Azzad Asset Management Inc. ADV Purchases Shares of 16,847 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Azzad Asset Management Inc. ADV acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,847 shares of the specialty pharmaceutical company's stock, valued at approximately $552,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Woodline Partners LP lifted its stake in shares of Supernus Pharmaceuticals by 124.8% in the 4th quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock valued at $15,326,000 after purchasing an additional 235,257 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Supernus Pharmaceuticals by 248.0% during the 4th quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company's stock worth $10,581,000 after buying an additional 208,552 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth $6,847,000. Great Lakes Advisors LLC acquired a new stake in Supernus Pharmaceuticals in the 4th quarter valued at about $6,131,000. Finally, D. E. Shaw & Co. Inc. raised its holdings in Supernus Pharmaceuticals by 33.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 545,658 shares of the specialty pharmaceutical company's stock valued at $19,731,000 after acquiring an additional 136,870 shares in the last quarter.

Wall Street Analyst Weigh In

SUPN has been the subject of several recent analyst reports. Wall Street Zen upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, May 16th. Cantor Fitzgerald restated a "neutral" rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Up 1.3%

Shares of Supernus Pharmaceuticals stock traded up $0.41 during trading on Monday, reaching $32.44. The company's stock had a trading volume of 1,197,330 shares, compared to its average volume of 483,608. The business has a 50 day moving average price of $32.02 and a 200-day moving average price of $34.32. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.55 and a 12-month high of $40.28. The company has a market capitalization of $1.82 billion, a P/E ratio of 30.32 and a beta of 0.71.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.